<DOC>
	<DOC>NCT02734862</DOC>
	<brief_summary>The purpose of this study is to determine if intravenous CD101 is safe and effective in the treatment of candidemia when compared to caspofungin (followed by oral fluconazole).</brief_summary>
	<brief_title>STRIVE: CD101 Compared to Caspofungin Followed by Oral Step Down Treatment in Subjects With Candidemia</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Fungemia</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>mycological diagnosis of candidemia (at least 1 blood culture positive for Candida or positive test for Candida from a sponsor approved rapid diagnostic test) life expectancy of greater than 72 hours female subjects of child bearing potential &lt;2 years post menopausal must agree to one barrier method and one highly effective method of birth control or sexual abstinence. male subjects must agree to use one barrier method of birth control or sexual abstinence provide informed consent presence of one or more systemic signs attributable to candidemia documented or suspected invasive candidiasis including intraabdominal infection, endocarditis, osteomyelitis, meningitis, or endophthalmitis neutropenia alanine aminotransferase or aspartate aminotransferase levels &gt;10 fold the upper limit of normal severe hepatic impairment in subjects with a history of chronic cirrhosis greater than 48 hours systemic antifungal treatment at approved doses to treat candidemia pregnant or lactating females who are nursing known hypersensitivity to CD101, caspofungin, any echinocandin, or to any of their excipients previous participation in this or any previous CD101 study recent use of an investigational medicinal product within 28 days of first dose of study drug or presence of an investigational device at the time of screening Principal Investigator considers the subject should not participate presence of indwelling vascular catheter or device that cannot be removed and is likely to be the source of candidemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>mycoses</keyword>
</DOC>